An interim policy published by the US Department of Health and Human Services on October 30 sets out how pharmacies and physicians can compound six selected peptides while the FDA works on a permanent framework. HHS, currently led by Secretary Robert F. Kennedy Jr., says it does not plan to penalize qualifying compounders who follow the new rules.

The move follows a July 2026 vote by the FDA's Pharmacy Compounding Advisory Committee, which reviewed seven peptides and recommended loosening restrictions on six of them. FDA staff pushed back, arguing the safety and effectiveness evidence was not convincing. That internal disagreement is the most interesting detail in the whole story and the one least likely to make the marketing copy.

What the policy actually covers

This is about compounding, not approval. Compounding is a pharmacist or physician mixing ingredients for an individual patient, and the resulting product is not reviewed the way a manufactured drug is.

The policy is limited to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional patient-specific prescriptions. It does not open the door to manufacturers, online sellers, or wellness companies mass-producing peptide products.

Why the restrictions existed

In 2023 the FDA placed nearly 20 peptides in Category 2, its designation for substances considered risky because of possible immune responses, questionable ingredient sourcing, or unproven human effects. The agency has flagged immunogenicity, peptide clumping, impurities, and contamination as specific concerns.

Identity is the other problem. A bottle may claim one peptide and contain the wrong sequence, the wrong dose, or something else entirely.

The guardrails attached

Compounders must source from registered manufacturers, obtain certificates of analysis, and test for identity, purity, potency, and contaminants. Serious adverse events go to the FDA, compounded products may contain only one active peptide from the list, and labels must state the product is compounded and not for resale.

What happens next

Analysts quoted in the coverage put a more accessible peptide market at $2 to 3 billion, with telehealth firms including Hims and Hers already discussing peptide offerings. The Federal Register notice carries a two-week public comment window, and HHS can tighten the policy if safety problems emerge. For compounds like BPC-157, TB-500, MOTS-c, and epitalon, most of the published evidence still comes from animal work or small early trials, which is a very different thing from regulatory access.